Eptinezumab
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Eptinezumab: From Migraine Prevention to Migraine with Brainstem Aura
One-Sentence Summary
Eptinezumab is an anti-CGRP (calcitonin gene-related peptide) monoclonal antibody already approved for prevention of episodic/chronic migraine. The TxGNN model predicts it may also be effective for migraine with brainstem aura (formerly basilar-type migraine), but this direction currently has 0 clinical trials and 0 publications in this evidence pack, and this subtype has historically been excluded from major anti-CGRP mAb trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Migraine prevention (episodic/chronic), per the drug’s known approved use — not separately confirmed in local regulatory records here |
| Predicted New Indication | Migraine with brainstem aura |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L3 |
| EU Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (DrugBank query pending, flagged as a High-severity data gap). Based on known information, Eptinezumab is an anti-CGRP monoclonal antibody already approved for migraine prevention in adults with episodic or chronic migraine. CGRP signaling is the central pathogenic pathway in migraine, including migraine with aura.
Migraine with brainstem aura is a clinical subtype of migraine with aura, sharing the same underlying trigeminovascular/CGRP pathway as the already-approved indication — making the mechanistic link biologically plausible as a subgroup extrapolation rather than a novel mechanism.
However, this subtype involves brainstem-localizing aura symptoms, and major anti-CGRP mAb Phase 3 trials (e.g., PROMISE-1/2) have typically excluded patients with basilar-type/brainstem aura migraine, out of caution regarding the vasoconstrictive/vasodilatory implications of blocking CGRP in a population with suspected vertebrobasilar vascular involvement. This means the prediction rests on mechanistic reasoning from the parent indication rather than direct subtype-specific evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
EU Market Information
No marketing authorization on record for this product in this evidence pack (0 licenses; market status: not marketed).
Safety Considerations
Please refer to the SmPC for safety information.
Note: TFDA label warnings/contraindications are marked as a Blocking data gap (DG001) — this must be resolved before any S1 safety review can proceed, particularly given the theoretical vascular considerations relevant to the brainstem aura subtype.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic rationale (shared CGRP pathway with the approved migraine indication) is plausible, but there is no direct clinical trial or literature evidence for this specific subtype, and a Blocking-severity safety data gap (missing TFDA label/warnings) currently prevents even an initial safety review.
To proceed, the following is needed:
- TFDA label/warnings and contraindications (DG001, Blocking)
- Confirmed mechanism of action detail via DrugBank API (DG002, High)
- Targeted literature/trial search specifically for CGRP monoclonal antibodies in basilar-type/brainstem aura migraine, since large pivotal trials excluded this subgroup
- Specific evaluation of vascular safety signals given the historical exclusion rationale for this subtype in CGRP mAb trials
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.